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Background: We sought to quantify temporal patterns in baseline risk, treatment, and outcomes of non-ST elevation acute coronary syndrome 
(NSTE ACS) patients enrolled in randomized clinical trials (RCT) over a 15-year period using available databases from 7 major multinational RCTs of 
glycoprotein IIb/IIIa inhibition in NSTE ACS.
Methods: The study population comprised 40,782 patients enrolled from 1994-2008 in PURSUIT, PRISM, PRISM-PLUS, PARAGON A, PARAGON B, 
GUSTO IV-ACS, and EARLY ACS. Patient characteristics, co-therapies, and outcomes were temporally mapped to 4 time domains describing time 
periods of randomization. Tests of statistical trend were performed using randomization month as a continuous variable.
Results: Over time, patient age increased, and patients were more likely to have diabetes, prior heart failure, and positive cardiac markers at 
randomization, but less often had prior myocardial infarction (Table). Use of thienopyridines, statins, angiotensin-converting enzyme inhibitors, and 
beta-blockers increased markedly. Composite death or myocardial infarction rates decreased, but mortality remained unchanged.
Conclusion: Despite enrollment of patients with substantially higher risk profiles into these RCTs of NSTE ACS, with concurrent increases in the use 
of evidence-based co-therapies, short-term mortality risk has remained constant over the past 15 years. These data add insight into future trends in 
the clinical substrate and specific outcomes driving RCTs. 
Table. Temporal Trends in Clinical Trials of NSTE ACS from 1994-2008
Time Domain
P Value for Time Trend1994-96 1997-99 2000-05 2006-08
# of patients 17,655 11,679 3817 7631
Population Characteristics
Age 64 (55, 71) 65 (56, 73) 67 (59, 75) 67 (60, 75) < 0.0001
Women 34.3 35.7 34.7 31.8 0.3329
Diabetes 21.9 22.3 25.2 30.0 < 0.0001
Prior MI 36.5 31.0 28.4 27.7 < 0.0001
Prior heart failure 7.6 9.3 10.6 11.8 < 0.0001
Cardiac marker + 31.1 42.9 55.2 89.5 <0.0001
In-hospital Co-therapy
Aspirin 96.0 98.2 96.4 97.6 < 0.0001
Thienopyridine 16.3 17.8 47.3 92.1 < 0.0001
Statin 21.1 19.6 82.8 87.4 < 0.0001
ACE inhibitor 34.7 33.0 52.2 70.0 < 0.0001
Beta-blocker 74.0 57.1 85.5 87.5 < 0.0001
30-day Outcomes
Death or MI 12.6 10.1 10.8 11.1 0.0381
Death 3.4 3.6 3.2 2.9 0.3431
Categorical variables expressed as percentages; continuous variables expressed as median (25th, 75th percentile). MI = myocardial infarction, ACE 
= angiotensin-converting enzyme.
